Advanced

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

Giralt, S.; Stadtmauer, E. A.; Harousseau, J. L.; Palumbo, A.; Bensinger, W.; Comenzo, R. L.; Kumar, S.; Munshi, N. C.; Dispenzieri, A. and Kyle, R., et al. (2009) In Leukemia 23(10). p.1904-1912
Abstract
Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell... (More)
Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions. Leukemia (2009) 23, 1904-1912; doi: 10.1038/leu.2009.127; published online 25 June 2009 (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
high-dose therapy, stem cell collection, myeloma, plerixafor, IMWG, guidelines
in
Leukemia
volume
23
issue
10
pages
1904 - 1912
publisher
Nature Publishing Group
external identifiers
  • wos:000270816300024
  • scopus:70350091086
ISSN
1476-5551
DOI
10.1038/leu.2009.127
language
English
LU publication?
yes
id
6931d0c7-69c9-4f45-8319-a19187005607 (old id 1506219)
date added to LUP
2009-11-23 16:17:13
date last changed
2017-11-26 03:38:12
@article{6931d0c7-69c9-4f45-8319-a19187005607,
  abstract     = {Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions. Leukemia (2009) 23, 1904-1912; doi: 10.1038/leu.2009.127; published online 25 June 2009},
  author       = {Giralt, S. and Stadtmauer, E. A. and Harousseau, J. L. and Palumbo, A. and Bensinger, W. and Comenzo, R. L. and Kumar, S. and Munshi, N. C. and Dispenzieri, A. and Kyle, R. and Merlini, G. and San Miguel, J. and Ludwig, H. and Hajek, R. and Jagannath, S. and Blade, J. and Lonial, S. and Dimopoulos, M. A. and Einsele, H. and Barlogie, B. and Anderson, K. C. and Gertz, M. and Attal, M. and Tosi, P. and Sonneveld, P. and Boccadoro, M. and Morgan, G. and Sezer, O. and Mateos, M. V. and Cavo, M. and Joshua, D. and Turesson, Ingemar and Chen, W. and Shimizu, K. and Powles, R. and Richardson, P. G. and Niesvizky, R. and Rajkumar, S. V. and Durie, B. G. M.},
  issn         = {1476-5551},
  keyword      = {high-dose therapy,stem cell collection,myeloma,plerixafor,IMWG,guidelines},
  language     = {eng},
  number       = {10},
  pages        = {1904--1912},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)},
  url          = {http://dx.doi.org/10.1038/leu.2009.127},
  volume       = {23},
  year         = {2009},
}